Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Firms Petition To Down-Classify Cranial Stimulators As FDA Plans PMA Rule

This article was originally published in The Gray Sheet

Executive Summary

Product makers Electromedical Products International, Fisher Wallace Laboratories and Neuro-Fitness each argue that the devices should be reclassified from class III to class II, with special controls, rather than be subject to PMA requirements.

You may also be interested in...



Panel Recommends PMAs For Cranial Electrotherapy Stimulators

FDA’s Neurological Devices panel recommends that pre-amendment cranial electrotherapy stimulator devices should remain in class III, with PMA requirements, due to a lack of efficacy data.

FDA Seeks PMA Requirements For More Pre-Amendment Devices

FDA is proposing to require pre-market approval applications for three class III, pre-amendment device types in the cardiovascular and neurologic device spaces.

FDA Panel Endorses PMAs For Electroshock Therapy Devices

A recent vote by an FDA advisory panel favoring more stringent regulation of electroconvulsive therapy devices is not likely to jeopardize future availability of the products on the market, according the panel's chairman.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT030721

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel